Article
Multidisciplinary Sciences
Laura Pizzuti, Maddalena Barba, Marco Mazzotta, Eriseld Krasniqi, Marcello Maugeri-Sacca, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Domenico Sergi, Daniele Marinelli, Giancarlo Paoletti, Silverio Tomao, Andrea Botticelli, Paolo Marchetti, Nicola Tinari, Antonino Grassadonia, Maria Rosaria Valerio, Rosanna Mirabelli, Maria Agnese Fabbri, Nicola D'Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Icro Meattini, Mirco Pistelli, Francesco Giotta, Vito Lorusso, Carlo Garufi, Antonio Russo, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Angela Vaccaro, Letizia Perracchio, Anna di Benedetto, Theodora Daralioti, Isabella Sperduti, Ruggero De Maria, Angelo Di Leo, Giuseppe Sanguineti, Gennaro Ciliberto, Patrizia Vici
Summary: The study found that patients with HER2-positive mBC with discordant HER2 status in early BC may have different clinical, biological, and prognostic behavior compared to HER2-concordant patients. These patients showed higher expression of estrogen and/or progesterone receptor, lower rate of brain metastases, and longer disease-free interval.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Na Zhao, Chunxia Qu, Yan Yang, Huihui Li, Yueyue Li, Hongbo Zhu, Zhiguo Long
Summary: This study revealed the correlation between dysregulated cholesterol metabolism and prognosis of multiple myeloma (MM). A prognostic signature was established and validated, showing good prognostic performance and correlation with clinical parameters. Functional and immune analysis indicated the association between metabolic pathways and immune status with risk score. The development and validation of this prognostic signature are expected to aid in predicting prognosis and guiding precision treatment for MM.
SCIENTIFIC REPORTS
(2023)
Editorial Material
Oncology
Yuqing Zhang, Rolf A. Brekken
Summary: The study challenges the functional significance of Tie2-expressing macrophages in tumor angiogenesis and relapse after chemotherapy, highlighting the need for reconsideration of Tie2 as a therapeutic target or prognostic indicator.
Review
Biochemistry & Molecular Biology
Pankaj Ahluwalia, Ravindra Kolhe, Gagandeep K. Gahlay
Summary: This review emphasizes composite prognostic scores from diverse resources with clinical utility in CRC, highlighting the importance of gene-expression based prognostic risk scores in improving the management of the disease.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Oncology
Romika Kumari, Muntasir Mamun Majumder, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Nina N. Nupponen, Fredrik Lehmann, Caroline A. Heckman
Summary: This study evaluated the biological significance of esterase expression in multiple myeloma (MM) by analyzing gene expression profiling and genomic variants in patients with newly diagnosed MM (NDMM) or relapsed/refractory MM (RRMM). High or low expression of specific esterases in MM, such as UCHL5, SIAE, ESD, PAFAH1B3, PNPLA4, and PON1, were significantly altered as patients progressed from NDMM to RRMM. Certain esterases, like OVCA2, PAFAH1B3, SIAE, USP4, and PCED1B, were identified as poor prognostic markers, suggesting their potential role in myeloma biology.
BRITISH JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Hiroshi Arinami, Yuichiro Watanabe, Yutaro Suzuki, Misuzu Tajiri, Nobuto Tsuneyama, Toshiyuki Someya
Summary: The pathophysiology of major depressive disorder (MDD) and schizophrenia is related to changes in cortisol and insulin-like growth factor 1 (IGF-1) levels. This study investigated the differences in serum cortisol and IGF-1 levels between patients with MDD, schizophrenia, and healthy controls. The results showed that cortisol levels were higher in schizophrenia patients compared to MDD patients and controls, while MDD patients had higher cortisol levels compared to controls. Both patient groups had higher IGF-1 levels compared to controls, with no significant difference between MDD and schizophrenia patients. These findings suggest pathophysiological differences between these disorders.
SCIENTIFIC REPORTS
(2023)
Article
Gastroenterology & Hepatology
Michael Rohr, Jihad Aljabban, Trina Rudeski-Rohr, Spencer Lessans, Sai Preethi Nakkina, Dexter Hadley, Xiang Zhu, Deborah A. Altomare
Summary: Through transcriptomic meta-analysis, distinct expression profiles between nuclear and membrane BARs were identified with prognostic relevance in gastric cancer, suggesting the need for further investigation into their roles in cancer development and progression. High expression of membrane BARs, but not nuclear BARs, was associated with poor prognosis and unfavorable clinicopathologic features, indicating potential as biomarkers for gastric cancer prognosis.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2021)
Article
Cell Biology
Jian Zhou, Gen Wu, Zhongyi Tong, Jingjing Sun, Jing Su, Ziqin Cao, Yingquan Luo, Wanchun Wang
Summary: The expression levels of SMC1A and SMC2 are significantly associated with poor prognosis in sarcoma, suggesting they may serve as potential prognostic biomarkers.
Review
Pharmacology & Pharmacy
Michael Gekle, Virginie Dubourg, Gerald Schwerdt, Ralf A. Benndorf, Barbara Schreier
Summary: EGFR plays a critical role in the regulation of vascular function and pathogenesis of cardiovascular diseases through the interplay with AT1R.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Genetics & Heredity
Angela Tolwani, Magdalena Matusiak, Nam Bui, Erna Forgo, Sushama Varma, Lucia Baratto, Andrei Iagaru, Alexander J. Lazar, Matt van de Rijn, Joanna Przybyl
Summary: Metabolic reprogramming and increased glucose uptake are key features of cancer, including leiomyosarcoma (LMS). Analysis of transcriptomic profiles in different subtypes of LMS revealed activation of the hexosamine biosynthesis pathway (HBP) in subtype 2 tumors. GFPT2, a key enzyme in HBP, was found to be expressed in a subset of LMS tumors and associated with poor outcome in uterine LMS. The data indicate HBP as a potential therapeutic target in a subtype of LMS.
NPJ GENOMIC MEDICINE
(2021)
Article
Oncology
Zhenling Zhang, Yuxin Zhang, Si Lao, Jian Qiu, Ziang Pan, Xiaoying Feng
Summary: This study identified IGF-1R and Livin as potential biomarkers for colorectal cancer (CRC) tumorigenesis. High expression of IGF-1R and Livin was associated with clinicopathological features of CRC and IGF-1R promoter methylation level. Additionally, elevated levels of IGF-1R and Livin were independent risk factors for stage and metastasis, and high expression of these proteins correlated with prolonged overall disease-free survival in CRC patients.
Article
Oncology
Ivana Lagreca, Vincenzo Nasillo, Patrizia Barozzi, Ilaria Castelli, Sabrina Basso, Sara Castellano, Ambra Paolini, Monica Maccaferri, Elisabetta Colaci, Daniela Vallerini, Patrizia Natali, Daria Debbia, Tommaso Pirotti, Anna Maria Ottomano, Rossana Maffei, Francesca Bettelli, Davide Giusti, Andrea Messerotti, Andrea Gilioli, Valeria Pioli, Giovanna Leonardi, Fabio Forghieri, Paola Bresciani, Angela Cuoghi, Monica Morselli, Rossella Manfredini, Giuseppe Longo, Anna Candoni, Roberto Marasca, Leonardo Potenza, Enrico Tagliafico, Tommaso Trenti, Patrizia Comoli, Mario Luppi, Giovanni Riva
Summary: This study sheds light on the dynamics of MM-specific T cells in patients with MGUS/SMM and introduces a new prognostic tool called MaMs T-cell assay, which may serve as an immunologic marker for effective disease control. The findings suggest that this assay can be routinely applied for risk assessment and prognostic evaluation in patients with monoclonal gammopathies.
Article
Cell Biology
Aneta Szudy-Szczyrek, Radoslaw Mlak, Michal Mielnik, Marcin Mazurek, Sylwia Chocholska, Martyna Podgajna, Michal Szczyrek, Iwona Homa-Mlak, Teresa Malecka-Massalska, Marek Hus
Summary: High expression of miRNA-8074 is significantly associated with poor prognosis in multiple myeloma patients.
Review
Biochemistry & Molecular Biology
Minlan Yuan, Biao Yang, Gerson Rothschild, J. John Mann, Larry D. Sanford, Xiangdong Tang, Canhua Huang, Chuang Wang, Wei Zhang
Summary: Major depressive disorder (MDD) affects millions of people worldwide, with genetics accounting for only a portion of the risk. Recent studies have shown that environmental factors can impact MDD through epigenetic modifications, which lead to various abnormalities in the brain. Understanding these modifications could provide insights into the heterogeneous nature of MDD and potentially lead to new therapeutic targets.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Review
Biochemistry & Molecular Biology
Damon Fard, Enrico Giraudo, Luca Tamagnone
Summary: This article discusses the role of Semaphorins and their receptors, Plexin and Neuropilin, in the progression of pancreatic cancer. These signaling molecules regulate neurons, endothelial cells, immune cells, and the microenvironment of tumors.
TRENDS IN MOLECULAR MEDICINE
(2023)
Review
Economics
Mimi Choon-Quinones, Dirk Hose, Zoltan Kalo, Tamas Zelei, Jean-Luc Harousseau, Brian Durie, Paul Keown, Mike Barnett, Ivett Jakab
Summary: Decision-aids (DAs) can assist in shared decision-making by providing evidence-based information for healthcare professionals, patients, and caregivers. However, current DAs lack a comprehensive framework of decision factors.
Article
Oncology
Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M. Knight, Nathan De Beule, Gamze Ates, Ann Massie, Jerome Moreaux, Anke Maes, Elke De Bruyne, Karin Vanderkerken, Eline Menu, Erica K. Sloan, Kim De Veirman
Summary: This study investigates the potential therapeutic effects of beta-blockers, specifically targeting the beta(2)-adrenergic receptor, in multiple myeloma treatment. The blockade of beta(2)-adrenergic receptors reduces cell viability, induces apoptosis and autophagy, and modulates cancer cell metabolism. Combining beta(2)AR blockade with other drugs enhances apoptosis in multiple myeloma cells.
JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Elias K. Mai, Stefanie Huhn, Kaya Miah, Alexandra M. Poos, Christof Scheid, Katja C. Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W. Blau, Mathias Haenel, Hans J. Salwender, Axel Benner, Marc S. Raab, Hartmut Goldschmidt, Niels Weinhold
Summary: Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. Our study found that MS negativity was significantly associated with improved progression-free survival (PFS) in multiple myeloma patients, even in those patients with complete response (CR). Combining MS and baseline cytogenetics improved the prediction of outcome, and sequential MS combined with baseline disease features and minimal residual disease (MRD) can further improve its clinical value.
BLOOD CANCER JOURNAL
(2023)
Review
Economics
Mimi Choon-Quinones, Tamas Zelei, Bertalan Nemeth, Manna Toth, Xiao Yang Jia, Mike Barnett, Paul Keown, Brian Durie, Jean-Luc Harousseau, Dirk Hose, Zoltan Kalo
Summary: The aim of this study was to review economic evaluations of health technologies in multiple myeloma (MM) and provide recommendations for future analyses. A systemic literature review was conducted and it was found that most economic analyses were from high-income countries, while evaluations from middle-income countries were rare. Diagnostic technologies and integrated care were rarely modelled, and there was a lack of evaluations regarding minimal residual disease (MRD).
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Oncology
Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Eline Menu, Holly Evans, Andrew Chantry, Nathan De Beule, Dirk Hose, Marie Toerngren, Helena Eriksson, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
Summary: This study reveals the dual therapeutic effects of the immunomodulator tasquinimod in multiple myeloma patients, including inhibition of tumor cell proliferation and promotion of immune activity. The results suggest that tasquinimod can inhibit immunosuppressive myeloid cells in the bone marrow by targeting S100A9, and enhance T cell activity and functionality.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
L. Baert, B. Manfroi, M. Quintero, O. Chavarria, P. V. Barbon, E. Clement, A. Zeller, T. Van Kuppevelt, N. Sturm, J. Moreaux, A. Tveita, B. Bogen, T. McKee, B. Huard
Summary: Multiple myeloma is a hematological neoplasm derived from plasma cells in the bone marrow. A subpopulation of cells called 10e4(+) cells, which have high resistance to multiple myeloma drugs, bind to the protein APRIL through heparan sulfate chains on syndecan-1. These cells have high proliferation activity and are able to form colonies in 3D cultures. They can develop in the bone marrow after intravenous injection and become more resistant to drugs after treatment. The enzyme HS3ST3a1 plays a role in modifying syndecan-1 to confer reactivity to 10e4 and APRIL binding. Targeting this enzyme could potentially improve drug resistance control in multiple myeloma.
Article
Genetics & Heredity
Mohammad Salma, Elina Alaterre, Jerome Moreaux, Eric Soler
Summary: Var vertical bar Decrypt is a web-based tool designed to extract relevant functional information from whole-exome sequencing (WES) data. It offers various filtering and analysis tools for prioritizing gene variants. By using Var vertical bar Decrypt, we successfully identified known disease oncogenes and novel putative drivers in WES datasets of acute erythroid leukemia patients.
EPIGENETICS & CHROMATIN
(2023)
Article
Hematology
Sarah Bonnet, Serge Carillo, Baptiste Legrand, Barbara Burroni, Thierry Lavabre-Bertrand, Guilhem Requirand, Nicolas Robert, Lea Fornero, Ahmed Al Mansoori, Jerome Moreaux, Guillaume Cartron, Ludovic Gabellier, Charles Herbaux
Summary: This case study describes a patient with extreme thrombocytosis who unfortunately had a rapidly fatal outcome. The cause of the thrombocytosis remained unknown and the patient did not show signs of myelofibrosis. However, dysplastic megakaryocytes were observed. The patient had a novel variant of the CALR gene in exon 3 (C105S), as well as mutations in ASXL1, U2AF1, and EZH2. These mutations were found in myeloid cells but not in lymphoid cells. The patient was diagnosed with a rare case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). Due to the high risk of thrombosis, the patient was treated with hydroxycarbamide. As the hematological status worsened, two new mutations, SETBP1 and ETV6, appeared, while the CALR mutation and the three other mutations identified in the chronic stage were still detectable. These findings suggest that the CALR variant may contribute to the pathogenesis of MDS/MPN in this patient.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Florian Richter, Clara Henssen, Tim Alexander Steiert, Tobias Meissner, Anne-Sophie Mehdorn, Christoph Roecken, Andre Franke, Jan-Hendrik Egberts, Thomas Becker, Susanne Sebens, Michael Forster
Summary: Esophageal cancer (EC) has a high mortality rate, and optimizing therapies and dynamically adapting to individuals is crucial. Liquid biopsy is an increasingly important method for residual disease monitoring, but conflicting detection rates and varying levels of circulating tumor DNA (ctDNA) have been observed in previous studies. This study aims to resolve this discrepancy and found that ctDNA in blood can be used for therapy monitoring of EC patients. A combination of solid and liquid samples should be used to guide individualized EC therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Oncology
Djamila Chemlal, Emmanuel Varlet, Amelie Machura, Sara Ovejero, Guilhem Requirand, Nicolas Robert, Guillaume Cartron, Elina Alaterre, Caroline Bret, Laure Vincent, Charles Herbaux, Giacomo Cavalli, Angelique Bruyer, Hugues De Boussac, Jerome Moreaux
Article
Medical Laboratory Technology
Emilia Boris, Alexandre Theron, Valentin Montagnon, Nicolas Rouquier, Marion Almeras, Jerome Moreaux, Caroline Bret
Summary: This study aimed to investigate the landscape of 7 leukemia-associated phenotype (LAP) markers in B acute lymphoblastic leukemia (B ALL). The expression levels of these markers in normal leukocytes, normal B cell differentiation, and B lymphoblasts at diagnosis of B ALL were evaluated. The study also examined the prognostic value of these markers using Maxstat R algorithm.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Meeting Abstract
Oncology
Catharina Muylaert, Lien Ann Van Hemelrijck, Elina Alaterre, Nicolas Robert, Guilhem Requirand, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jerome Moreaux, Elke De Bruyne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Inge Oudaert, Judith Lind, Osman Aksoy, Catharina Muylaert, Hatice Satilmis, Sylvia Faict, Jerome Moreaux, Kim De Veirman, Elke De Bruyne, Sonia Vallet, Karin Vanderkerken, Klaus Podar, Eline Menu
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Sara Ovejero, Julie Devin, Tatiana Caneque, Laura Henry, Laura Alibert, Guilhem Requirand, Nicolas Robert, Alizee Steer, Amelie Machura, Christophe Hirtz, Angelique Bruyer, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Caroline Bret, Jerome Moreaux
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Laure Dutrieux, Guillemin Antoine, Lin Yea-Lih, Malik Lutzmann, Guilhem Requirand, Nicolas Robert, Laure, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Michel Cogne, Philippe Pasero, Jerome Moreaux
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)